Somatostatin receptor Inhibitors
6 drugsAbout Somatostatin receptor
The Somatostatin receptor (SSTR) is a GPCR that mediates the effects of somatostatin, regulating various physiological processes. SSTR activation modulates hormone release and cell growth. It is a valuable drug target implicated in a variety of therapeutic areas.
Genetic evidence offers moderate support for SSTR2 as a therapeutic target, with associations to pneumonitis and smoking initiation (score 0.51). Colocalization studies show strong eQTL/pQTL signals (max H4: 0.99). This suggests potential for genetically informed drug development.
SSTR is targeted by 6 FDA-approved small molecule drugs, including OCTREOTIDE ACETATE, SANDOSTATIN LAR, and MYCAPSSA. These drugs are used to treat a range of conditions, with approvals spanning from 1998 to 2024.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Somatostatin Receptor Positive (SSTR+) with only 1 trials.
Somatostatin receptor Genetic Evidence Moderate
Genetic evidence provides moderate support for SSTR2, with a max score of 0.51 linked to pneumonitis and smoking initiation.
Further investigation of the genetic links to pneumonitis and smoking initiation may reveal novel therapeutic opportunities.
Evidence Across Diseases
4 totalGWAS and other genetic studies link SSTR2 to 4 diseases.
🔗 Colocalization Evidence 3 strong
max H4: 0.99eQTL/pQTL signals for SSTR2 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Somatostatin receptor Drugs
Five companies have approved SSTR-targeting drugs, including WEST-WARD PHARMS INT, IPSEN PHARMA, and Novartis.
The presence of multiple players suggests a competitive market, requiring a differentiated strategy for new entrants.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| OCTREOTIDE ACETATE | Viatris | 2005 | 3 |
| SOMATULINE DEPOT | IPSEN PHARMA | 2007 | 3 |
| MYCAPSSA | CHIESI | 2020 | 1 |
Somatostatin receptor Drug Modality Landscape
Modalities
Routes of Administration
Somatostatin receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Somatostatin receptor Clinical Trials 108 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 25 | 15 | 5 | 4 | 75% |
| Phase 2 | 38 | 23 | 10 | 5 | 70% |
| Phase 3 | 30 | 16 | 3 | 11 | 84% |
| Phase 4 | 15 | 9 | 4 | 2 | 69% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Somatostatin receptor Drug Approval Timeline (1998 - 2024)
The first SSTR-targeting drug was approved in 1998, with the most recent approval in 2024.
The continued approvals indicate sustained interest, but also suggest increasing market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 6 companies competing
- • Market share by company
Full Drug Portfolio
- • All 6 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 6-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 91 clinical trials targeting Somatostatin receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities